Search

The article discusses research which examined the utility of the Decipher Bladder genomic classifier in patients with muscle invasive bladder cancer (MIBC). It references a study by Yair Lotan et al, published in a 2021 issue of the "Journal of Urology." Topics covered include the ability of the assay to identify tumors that are more likely to respond to neoadjuvant chemotherapy (NAC), and findings which show the clinical utility of implementing molecular subtyping.

An interview with urology professor Dr. Chad R. Ritch and postgraduate year 5 (PGY5) resident Dr. Jonathan E. Katz, is presented. Among the issues they discussed include the process in creating the free mobile application (app) BlaTUR designed to help clinicians manage and risk-stratify patients with bladder cancer, the significance of the app for urologists who treat bladder cancer, and the app's role in the future of health care in terms of becoming mobile-friendly and accessible to users.

The article discusses the advent of precision medicine for advanced bladder cancer treatment as of February 2020. Topics covered include the common fibroblast growth factor receptor (FGFR) early target mutation in bladder cancer, the erdafitinib (FGFR3) inhibitor, and the importance of early patient tissue testing for possible clinical trial participation in oral agent treatment for FGFR3. Also noted is the yet unclear patient management change from markers in development for bladder cancer.